ANS Testing

The symptoms arrive in fragments, rarely making a neat picture. A heart that races when you stand up. Unexplained fatigue that no amount of sleep resolves. Dizziness that sends you gripping the nearest wall. Sweating at the wrong times — or not sweating at all. For millions of patients, these experiences orbit a diagnosis that never quite materializes, cycling through specialist after specialist while the underlying cause goes unmeasured.

What most evaluations miss is the autonomic nervous system — the silent regulatory architecture controlling heart rate, blood pressure, digestion, temperature, and nearly every function the body manages without conscious effort. At RegenLife Centers for Integrative Pain & Weight Management, ANS testing gives these symptoms a measurable biological basis. It is not a single test but a clinical window: a way to see, with precision, how well the body's involuntary control systems are functioning — and what disruptions to those systems are contributing to symptoms that have otherwise defied explanation.

Key Takeaways

• More than 70 million people worldwide live with some form of dysautonomia — autonomic nervous system dysfunction — yet it remains widely underdiagnosed, undertreated, and underappreciated across conventional healthcare
• Cardiovascular autonomic neuropathy affects up to 15% of newly diagnosed diabetic patients and carries a mortality risk that is more than double that of diabetes without autonomic involvement
• 66% of long COVID patients demonstrate moderate-to-severe autonomic dysfunction on validated testing — making ANS testing one of the most relevant diagnostic tools in post-COVID care
• A standard ANS testing battery is non-invasive, takes 60–90 minutes, and can detect subclinical dysfunction before symptoms become debilitating — enabling earlier intervention and meaningful risk reduction

---

What the Autonomic Nervous System Actually Does — and Why Testing It Matters

The autonomic nervous system (ANS) operates entirely below the level of conscious awareness, coordinating the physiological processes that keep you alive and functional: heart rate, blood pressure regulation, breathing depth, digestive motility, temperature regulation, sweating, bladder control, and pupil response. It operates through two branches that must remain in dynamic balance: the sympathetic system (the accelerator — activating stress responses, raising heart rate and blood pressure) and the parasympathetic system (the brake — governing recovery, digestion, and calm).

When that balance is lost — through disease, injury, metabolic disruption, or nerve damage — the consequences are widespread. Because the ANS touches virtually every organ system, autonomic dysfunction produces symptom patterns that look different in every patient and are easily attributed to anxiety, deconditioning, or functional complaints.

The Scope of Autonomic Dysfunction

The range of conditions in which autonomic dysfunction plays a central, measurable role is broader than most patients — and many clinicians — realize:

• Diabetes — cardiovascular autonomic neuropathy (CAN) affects 7–15% of newly diagnosed patients and up to 90% of those with long-standing disease. Abnormal Valsalva responses in diabetics carry a 3.0x higher relative risk for primary cardiovascular events and a 4.5x higher relative risk for silent myocardial ischemia
• POTS and orthostatic disorders — postural orthostatic tachycardia syndrome affects over 3 million Americans, with 83% having been misdiagnosed with a psychological condition before receiving an accurate diagnosis and an average of 5.2 physicians seen before correct identification
• Long COVID — 66% of 2,314 long COVID patients in one study showed moderate-to-severe autonomic dysfunction; 76.7% of 332 long COVID patients showed dysautonomia symptoms on validated questionnaire
• Chronic fatigue (ME/CFS) and fibromyalgia — reduced heart rate variability predicts fatigue severity in ME/CFS, and 40–60% of fibromyalgia patients have objective small fiber neuropathy on skin biopsy
• Neurodegeneration — ANS testing distinguishes Parkinson's disease from multiple system atrophy (MSA), a distinction with profound prognostic consequence given MSA's mean survival of approximately 7 years from onset

The unifying problem is this: autonomic dysfunction is measurable well before it becomes symptomatic — but only if the right tests are ordered. A standard physical exam will not capture it. Routine bloodwork will not find it. ANS testing exists to detect what other evaluations miss.

---

Types of ANS Testing: What Each Measures

Autonomic nervous system testing is not a single procedure — it is a battery of complementary assessments, each probing a different functional pathway. No single test tells the full story; the diagnostic value comes from reading the results together, as a composite picture of how the autonomic system is performing across different demands.

Cardiovascular Reflex Tests

These tests assess how the heart rate and blood pressure respond to controlled physiological challenges, revealing the integrity of both sympathetic and parasympathetic pathways through the cardiovascular system:

• Deep Breathing Test (HRDB) — The patient breathes at six breaths per minute while the heart rate is monitored. A normal result shows heart rate rising on inhalation and falling on exhalation; blunted variation indicates impaired vagal (parasympathetic) function. This is among the most sensitive early markers of diabetic autonomic neuropathy
• Valsalva Maneuver — The patient exhales against resistance, producing predictable cardiovascular responses that trace the integrity of the baroreceptor reflex loop. A Valsalva ratio below 1.21 indicates abnormal autonomic control; this test distinguishes central from peripheral dysfunction and sympathetic from parasympathetic failure
• Head-Up Tilt Table Test (HUTT) — The patient is secured to a motorized table and tilted to 60–80 degrees while blood pressure and heart rate are monitored continuously for 30–45 minutes. This is the gold-standard diagnostic test for POTS, neurally mediated syncope, and orthostatic hypotension. A heart rate increase of 30 or more beats per minute on standing, sustained over 10 minutes, confirms POTS in adults
• Active Standing Test (30:15 ratio) — A shorter orthostatic challenge that captures the immediate reflex response to standing; a 30:15 ratio below 1.04 signals impaired parasympathetic adaptation
• Cold Pressor and Isometric Handgrip Tests — Both assess sympathetic activation under controlled stress; a diastolic blood pressure increase below 15 mmHg indicates sympathetic adrenergic impairment

Heart Rate Variability Analysis

Heart rate variability (HRV) — the beat-to-beat variation in the time between heartbeats — is one of the most sensitive, non-invasive windows into overall autonomic health. A healthy autonomic nervous system produces continuous, fine-tuned adjustments to cardiac rhythm; a compromised one produces rigid, metronomic patterns that reflect reduced adaptive capacity.

The clinical implications are substantial. Low HRV is associated with a 32–45% increased risk of a first cardiovascular event in people without known cardiovascular disease. In post-MI patients, an SDNN below 70 milliseconds on 24-hour Holter monitoring carries approximately a 4-fold higher mortality risk. Each standard deviation decrement in SDNN corresponds to roughly a 24% increase in sudden cardiac death risk.

HRV analysis interprets several parameters:

• SDNN — Overall HRV, reflecting combined sympathetic and parasympathetic regulation; the primary long-term cardiovascular risk marker
• RMSSD — Short-term beat-to-beat variation driven primarily by vagal activity; declines in POTS, post-COVID dysautonomia, and ME/CFS
• LF/HF ratio — The balance between sympathetic and parasympathetic domains; ratios above 2 indicate sympathetic predominance, found consistently in chronic stress, POTS, and post-COVID populations

HRV declines naturally at roughly 1–2% per year beginning around age 30, making age-adjusted interpretation essential.

Sudomotor (Sweat) Function Testing

The sweat glands are innervated exclusively by the sympathetic nervous system, making sweat function testing a precise window into postganglionic sympathetic fiber integrity — the same nerve fibers damaged early in diabetic neuropathy and small fiber polyneuropathy.

• QSART (Quantitative Sudomotor Axon Reflex Test) — Acetylcholine is delivered via iontophoresis at four standardized body sites (forearm, proximal leg, distal leg, foot). The sweat output at each site is quantified, revealing the distribution and severity of sudomotor nerve fiber loss. QSART is considered the most precise test for evaluating thermoregulatory nerve function and can detect fiber loss years before clinical symptoms develop
• Thermoregulatory Sweat Test (TST) — The patient is placed in a heated chamber that raises core body temperature by 1–1.4°C while a color-changing indicator powder reveals the pattern of sweating across the entire body surface. The percentage of anhidrosis (absent sweating) is calculated — in MSA, 67.4% of the body surface shows anhidrosis, compared to 1.7% in Parkinson's disease, a distinction with direct diagnostic significance
• Sympathetic Skin Response (SSR) — Skin electrical resistance changes triggered by acoustic, tactile, or electrical stimuli reflect the sweat gland's sympathetic innervation and provide a simple, reproducible adjunct measure

Validated Symptom Scoring

The COMPASS-31 (Composite Autonomic Symptom Score) is a validated 31-item questionnaire covering six autonomic domains: orthostatic intolerance, vasomotor symptoms, secretomotor function, gastrointestinal symptoms, bladder dysfunction, and pupillomotor changes. It provides a quantitative symptom burden score that calibrates well with objective test findings and has been validated across diabetes, multiple sclerosis, POTS, post-concussion syndrome, and long COVID.

---

What ANS Testing Reveals: Conditions It Detects and Guides

Autonomic nervous system testing is not diagnostic in isolation — it identifies functional impairment and guides its integration with clinical findings, imaging, and laboratory results. The conditions where it contributes most meaningfully include:

Diabetic Autonomic Neuropathy

Cardiovascular autonomic neuropathy (CAN) is the most dangerous and least recognized complication of diabetes. It precedes symptomatic cardiovascular disease by years and significantly amplifies cardiac event risk independent of other risk factors. The American Diabetes Association recommends screening for CAN at the time of Type 2 diabetes diagnosis and five years after a Type 1 diabetes diagnosis.

ANS testing detects CAN before resting heart rate or exercise tolerance have changed, enabling medication adjustments, lifestyle interventions, and cardiovascular monitoring strategies that reduce mortality risk in a window when they are still most effective.

Long COVID and Post-Viral Dysautonomia

Post-COVID autonomic dysfunction has emerged as one of the central mechanisms behind long COVID symptoms — fatigue, brain fog, exertional intolerance, racing heart, and orthostatic symptoms. A 2025 study in the Journal of the American College of Cardiology found that patients with long COVID showed persistent autonomic dysfunction comparable in severity to pure autonomic failure when adjusted for age and sex — with abnormalities persisting well beyond acute illness recovery.

ANS testing provides an objective basis for what long COVID patients have often been told is psychosomatic. A measurable tilt test result, a quantified HRV deficit, or an abnormal sweat distribution map converts a disputed symptom into a documented physiological finding — one that can guide treatment and support disability documentation where relevant.

Orthostatic Disorders: POTS, Syncope, and Orthostatic Hypotension

These conditions are definitionally diagnosed through the cardiovascular reflex battery. The tilt table test differentiates POTS from orthostatic hypotension, neurally mediated syncope from cardiogenic, and autonomic failure from hyperadrenergic states — distinctions that determine entirely different treatment pathways. Given that the average POTS patient sees 5.2 physicians before diagnosis, a structured ANS evaluation significantly compresses that timeline.

Cardiovascular Risk Stratification

Beyond diagnosing dysautonomia, HRV analysis contributes to cardiovascular risk assessment independent of standard lipid panels, ejection fraction, and stress testing. Low SDNN has been shown to predict 30-day mortality in acutely admitted medical patients at a 4-fold higher rate than those with preserved HRV, independent of admission diagnosis. For patients with heart failure, reduced HRV carries hazard ratios of 2.1–3.2 for sudden death beyond what ejection fraction alone predicts.

Chronic Fatigue, Fibromyalgia, and ME/CFS

In conditions where no structural abnormality is visible on imaging, ANS testing provides objective physiological evidence of nervous system dysfunction. Reduced RMSSD and total HRV power predict fatigue severity scores in ME/CFS. Adrenergic dysfunction patterns — elevated baseline adrenaline, atypical exercise responses — differentiate ME/CFS from fibromyalgia on functional testing, supporting more targeted treatment approaches.

Neurodegeneration: Parkinson's Disease and MSA

1 in 5 patients initially diagnosed with Parkinson's disease actually has multiple system atrophy — a distinction that carries profound consequences for prognosis and treatment. Thermoregulatory sweat testing, cardiac sympathetic scintigraphy, and the pattern of autonomic test abnormalities reliably distinguish between these diagnoses, enabling patients and families to make informed decisions based on accurate prognoses.

---

What Abnormal ANS Testing Results Mean in Practice

An autonomic testing battery is interpreted as a profile, not as a single finding. The results map onto three primary domains:

The interpretive value lies in the pattern across tests — which systems are affected, how severely, and whether the distribution suggests a preganglionic lesion (pointing toward central nervous system or spinal cord pathology) versus postganglionic (pointing toward peripheral neuropathy). This localization has direct implications for diagnosis and for determining which treatments are most likely to address root cause rather than manage symptoms.

---

Who Should Be Evaluated with ANS Testing

ANS testing is not exclusively for patients with dramatic, obvious dysautonomia symptoms. The conditions that warrant evaluation span a broader clinical picture:

• Unexplained fatigue, brain fog, or exertional intolerance that has not been explained by metabolic, thyroid, or sleep studies
• Dizziness, lightheadedness, or near-syncope on standing — especially if symptoms occur daily and have not been captured by standard cardiovascular workup
• Known diabetes (Type 1 or Type 2) — particularly with neuropathy symptoms, abnormal resting heart rate, or history of hypoglycemic unawareness
• Long COVID symptoms persisting beyond three months after acute illness, especially with orthostatic intolerance, fatigue, or cognitive symptoms
• Fibromyalgia or ME/CFS where a functional basis for symptoms has not been documented
• Unexplained cardiovascular symptoms — palpitations, exercise intolerance, heart rate irregularity — without a structural cardiac cause
• Parkinson's disease or other neurodegenerative diagnoses where clarification of autonomic involvement would change management
• Recurrent syncope that has not been resolved through standard cardiac and neurological evaluation
• Elevated cardiovascular risk in patients who want a more complete picture beyond standard lipid and blood pressure parameters

Standard ANS testing is non-invasive, involves no needles for the cardiovascular reflex battery, and takes approximately 60–90 minutes in a clinical setting. Preparation is straightforward: avoid caffeine for 8 hours, alcohol for 12 hours, and tobacco for 4 hours before the appointment. Most standard components are covered by Medicare under LCD L35124 when medically indicated, and commercial insurers typically cover testing when medically necessary.

---

ANS Testing at RegenLife Centers Cincinnati OH

At RegenLife Centers for Integrative Pain & Weight Management, ANS testing is integrated into a broader diagnostic and treatment framework — not ordered as an isolated procedure, but as part of understanding the full physiological picture for patients whose symptoms point toward autonomic involvement.

For patients managing chronic pain, fatigue, or complex symptom patterns, the autonomic nervous system is frequently a contributing factor that has not been directly evaluated. The findings from ANS testing inform a coordinated care plan that may include:

• Lifestyle medicine — addressing the metabolic, nutritional, and behavioral factors that drive autonomic imbalance, including sleep, inflammatory burden, and physical activity pacing
• Exercise therapy — structured conditioning programs that improve vagal tone, reduce sympathetic overdrive, and rebuild orthostatic tolerance in patients with POTS and post-COVID dysautonomia
• BrainTap therapy — neurostimulation approaches that support autonomic balance through guided relaxation and parasympathetic activation
• Hormone therapy — correcting thyroid, testosterone, or adrenal imbalances that impair autonomic function and amplify sympathetic tone
• Behavioral health — addressing the bidirectional relationship between chronic autonomic dysregulation and the psychological dimensions of persistent, unexplained symptoms
• Medical management — pharmacological support where medication review and adjustment can reduce autonomic burden or treat specific patterns identified on testing

The goal is not simply to document dysfunction — it is to understand what is causing it and what targeted interventions can improve it. ANS testing provides the foundation for that conversation: an objective, reproducible profile of where the nervous system is underperforming and what conditions need to change for function to improve.

---

If you have been experiencing unexplained fatigue, orthostatic symptoms, chronic pain, or post-COVID symptoms that have not been fully explained by prior evaluation, ANS testing at RegenLife Centers may provide the missing piece. Schedule a consultation to discuss whether autonomic function testing belongs in your diagnostic workup.

---